---
id: biograph-preventive-diagnostics
slug: biograph-preventive-diagnostics
entity_type: commercial
status: operational
data_completeness: high
last_researched: 2025-12-23
researcher: AI Assistant
version: 2.1
name: Biograph Preventive Diagnostics Platform
description: Comprehensive preventive health assessment platform that collects over 1,000 data points from more than 30 evaluations in a single visit. Uses advanced diagnostic technologies including whole-body MRI, CT coronary angiography, AI-powered vascular plaque characterization, multi-cancer early detection testing, multi-modal brain health assessments, metabolic evaluations, and quality of life assessments to enable early detection of diseases and optimize healthspan and lifespan.
mission: "To redefine healthy aging and set new industry standards for preventive health and diagnostics. Biograph aims to enable early detection of diseases before symptoms appear, allowing for proactive intervention to optimize healthspan and lifespan. The company's mission is to provide comprehensive, personalized health assessments that integrate advanced diagnostic technologies with AI-powered analysis to identify risks for cancer, cardiovascular disease, metabolic dysfunction, neurodegenerative disease, and quality of life factors."
entity_data:
  focus: Preventive health and diagnostics platform using advanced imaging, AI-powered analysis, and comprehensive biomarker testing to enable early detection of diseases and optimize healthspan and lifespan
  founded: 2025
  website: "https://www.biograph.com/"
  industry: Healthcare
  employees:
  note: Employee count not publicly disclosed
  legal_name: Biograph Inc.
  headquarters:
  city: San Mateo
  state: California
  address: San Mateo, California
  country: USA
taxonomy:
  geography: USA
  ai_technology:
  - Predictive ML/DL
  primary_focus:
  - Diagnostics & Preventive Health
  aging_approach:
  - Diagnostics/Age Assessment
  target_biology:
  - Metabolic Diseases
  development_stage: operational
  organization_type: commercial
  organization_subtype: operational
  therapeutic_modality: []
organizations:
  -
    name: Caristo Diagnostics
    role: partner
    org_type: company
    website: "https://www.caristo.com/"
    status: operational
    role_description: Research collaboration partner providing CaRi-Heart® and CaRi-Plaque™ AI technology for cardiovascular risk detection
  -
    name: Biograph
    role: primary
    org_type: company
    legal_name: Biograph Inc.
    founded: 2025
    website: "https://www.biograph.com/"
    status: operational
    role_description: Primary organization developing and operating Biograph Preventive Diagnostics Platform
products:
  -
    name: Biograph Preventive Diagnostics Platform
    type: platform
    status: Commercially available
    development_stage: operational
links:
  -
    url: "https://peterattiamd.com/podcast/"
    type: podcast
    title: The Drive with Peter Attia - Longevity Podcast
  -
    url: "https://www.peterattiamd.com/outlive/"
    type: book
    title: "Outlive: The Science and Art of Longevity by Dr. Peter Attia"
  -
    url: "https://www.siemens-healthineers.com/en-us/press-room/press-releases/biograph-vision-x-fda-clearance"
    type: press_release
    title: Siemens Healthineers Announces FDA Clearance of Biograph Vision.X PET/CT Scanner
  -
    url: "https://techcrunch.com/2025/02/28/startup-co-founded-by-longevity-guru-peter-attia-emerges-from-stealth/"
    type: news_article
    title: Startup co-founded by longevity guru Peter Attia emerges from stealth
  -
    url: "https://www.biograph.com/how-biograph-works"
    type: website
    title: How Biograph Works – Longevity Health Plan & Comprehensive Evaluation
  -
    url: "https://www.biograph.com/faq"
    type: website
    title: Frequently Asked Questions - Biograph Preventive Health & Longevity
  -
    url: "https://radiologybusiness.com/topics/healthcare-management/healthcare-economics/biograph-new-whole-body-mri-startup-launches-7500-membership-fee"
    type: news_article
    title: Biograph, a new whole-body MRI startup, launches with $7,500 membership fee
  -
    url: "https://www.prnewswire.com/news-releases/pioneering-the-future-of-heart-health-biograph-and-caristo-diagnostics-announce-first-of-its-kind-us-study-to-advance-ai-powered-prevention-302570592.html"
    type: press_release
    title: "Pioneering the Future of Heart Health: Biograph and Caristo Diagnostics Announce First-of-its-Kind U.S. Study to Advance AI-Powered Prevention"
  -
    url: "https://www.businesswire.com/news/home/20250520281301/en/Biograph-Opens-its-New-York-City-Clinic-Transforming-the-Personalized-Healthcare-Experience"
    type: press_release
    title: Biograph Opens its New York City Clinic, Transforming the Personalized Healthcare Experience
  -
    url: "https://www.businesswire.com/news/home/20250227400955/en/Biograph-the-Worlds-Most-Advanced-Preventive-Health-and-Diagnostics-Clinic-Launches-to-Redefine-Healthy-Aging-and-Set-New-Industry-Standards"
    type: press_release
    title: "Biograph, the World's Most Advanced Preventive Health and Diagnostics Clinic, Launches to Redefine Healthy Aging and Set New Industry Standards"
---

# Biograph Preventive Diagnostics Platform

## Description

Comprehensive preventive health assessment platform that collects over 1,000 data points from more than 30 evaluations in a single visit. Uses advanced diagnostic technologies including whole-body MRI, CT coronary angiography, AI-powered vascular plaque characterization, multi-cancer early detection testing, multi-modal brain health assessments, metabolic evaluations, and quality of life assessments to enable early detection of diseases and optimize healthspan and lifespan.

## Mission

To redefine healthy aging and set new industry standards for preventive health and diagnostics. Biograph aims to enable early detection of diseases before symptoms appear, allowing for proactive intervention to optimize healthspan and lifespan. The company's mission is to provide comprehensive, personalized health assessments that integrate advanced diagnostic technologies with AI-powered analysis to identify risks for cancer, cardiovascular disease, metabolic dysfunction, neurodegenerative disease, and quality of life factors.

## Company Information

**Legal Name**: Biograph Inc.
**Founded**: 2025
**Industry**: Healthcare
**Employees**: {"note":"Employee count not publicly disclosed","peak":null,"as_of":null,"current":null}
**Focus**: Preventive health and diagnostics platform using advanced imaging, AI-powered analysis, and comprehensive biomarker testing to enable early detection of diseases and optimize healthspan and lifespan
**Website**: https://www.biograph.com/

## Scientific Background

```yaml
ai_integration: AI is used for vascular plaque characterization from CT scans (through Caristo Diagnostics partnership), biomarker analysis, and predictive modeling to assess disease risk. The platform collects over 1,000 data points from 30+ evaluations to create personalized health assessments. AI enables pattern recognition across multiple biomarkers that would be difficult for human clinicians to integrate manually, potentially identifying risk patterns that emerge from the combination of multiple factors rather than individual markers.
biomarker_integration: The integration of over 1,000 data points from 30+ evaluations represents a systems biology approach to health assessment. Rather than focusing on individual biomarkers in isolation, the platform seeks to understand health as an integrated system. This approach recognizes that diseases often involve multiple pathways and that early indicators may be subtle and distributed across multiple systems. AI and machine learning enable the identification of complex patterns that may not be apparent through traditional single-marker analysis.
technological_context: "Biograph's approach is enabled by advances in several areas: (1) High-field MRI technology that enables rapid, high-resolution whole-body imaging, (2) AI and machine learning for image analysis and pattern recognition, (3) Liquid biopsy technologies for multi-cancer early detection, (4) Advanced cardiac CT imaging with AI enhancement, and (5) Integrated data platforms that can synthesize information from multiple sources. These technologies, while individually available, are rarely integrated into a comprehensive preventive health platform."
comprehensive_assessment: "The platform evaluates five key areas: (1) Cancer risk through whole-body MRI and multi-cancer early detection testing, (2) Cardiovascular disease through CT coronary angiography and AI plaque analysis, (3) Metabolic dysfunction through comprehensive metabolic evaluations, (4) Neurodegenerative disease risk through multi-modal brain health assessments, and (5) Quality of life factors including strength, movement quality, sleep, and stress. This comprehensive approach recognizes that aging and disease are multifactorial processes requiring integrated assessment."
early_detection_evidence: Scientific literature supports the value of early disease detection. Studies have shown that early-stage cancer detection significantly improves survival rates. For cardiovascular disease, early identification of risk factors and subclinical disease enables lifestyle and medical interventions that can prevent or delay disease progression. The challenge has been identifying cost-effective screening methods for asymptomatic individuals, which Biograph addresses through comprehensive, technology-enabled assessments.
whole_body_mri_screening: Whole-body MRI for screening asymptomatic individuals is an emerging field. While traditional screening focuses on specific organs or disease types, whole-body MRI offers comprehensive assessment in a single examination. Research suggests that whole-body MRI can detect a variety of conditions including cancers, vascular abnormalities, and structural anomalies. However, the approach requires careful consideration of false positives, incidental findings, and cost-effectiveness, which Biograph addresses through expert clinical review and personalized follow-up.
preventive_medicine_approach: "Biograph's platform is based on the principle that early detection of diseases before symptoms appear enables proactive intervention. The company integrates multiple diagnostic modalities including advanced imaging (whole-body MRI, CT coronary angiography), laboratory testing, and AI-powered analysis to identify health risks across multiple disease categories. This approach aligns with evidence-based preventive medicine principles that emphasize early intervention to improve health outcomes and reduce disease burden."
coronary_inflammation_detection: The partnership with Caristo Diagnostics represents a significant advance in cardiovascular risk assessment. Traditional risk factors (cholesterol, blood pressure) and imaging (coronary calcium scoring) provide valuable information but may miss early inflammatory processes. Coronary artery inflammation, detected through AI analysis of perivascular fat attenuation on CT scans, represents a novel biomarker that may identify cardiovascular risk before traditional markers become abnormal. This approach is based on research showing that inflammation plays a key role in atherosclerosis progression.
comparison_with_traditional_medicine: "Traditional healthcare is largely reactive, focusing on treatment after symptoms appear. Biograph's preventive approach aims to shift this paradigm by identifying risks and early disease before symptoms develop. While traditional screening programs (e.g., mammography, colonoscopy) focus on specific diseases, Biograph offers comprehensive multi-disease screening. The membership-based model addresses limitations of traditional insurance-based care, where preventive services may be limited or require symptoms for coverage."
```

## Lessons Learned

### Achievements

- Successfully launched comprehensive preventive health platform with two operational clinics
- Established partnership with Caristo Diagnostics for AI-powered cardiovascular risk detection
- Demonstrated high member satisfaction (>99%) and significant health impact (15%+ urgent findings rate)
- Created integrated platform combining advanced imaging, biomarker analysis, and AI-powered risk assessment

### Challenges

- High cost of comprehensive diagnostic services may limit accessibility to broader population
- Need to demonstrate value of preventive screening in asymptomatic individuals
- Integration of multiple diagnostic modalities and AI technologies requires sophisticated infrastructure
- Regulatory compliance for healthcare services and data privacy

### Impact on Field

Biograph represents a new model for preventive healthcare that integrates advanced diagnostic technologies with AI-powered analysis. By focusing on early detection in asymptomatic individuals, the company aims to shift healthcare from reactive to proactive. The partnership with Caristo Diagnostics demonstrates the potential for AI to enhance cardiovascular risk assessment beyond traditional methods. While the membership-based model limits accessibility, it may serve as a proof-of-concept for preventive health approaches that could be adapted for broader populations.

## Organizations

### Caristo Diagnostics
**Role in Project**: partner
**Role Description**: Research collaboration partner providing CaRi-Heart® and CaRi-Plaque™ AI technology for cardiovascular risk detection
**Organization Type**: company
**Status**: operational
**Website**: https://www.caristo.com/
**Description**: AI-powered cardiac risk assessment company providing CaRi-Heart® and CaRi-Plaque™ technology for coronary artery inflammation detection and plaque characterization

### Biograph
**Legal Name**: Biograph Inc.
**Role in Project**: primary
**Role Description**: Primary organization developing and operating Biograph Preventive Diagnostics Platform
**Organization Type**: company
**Status**: operational
**Founded**: 2025
**Website**: https://www.biograph.com/
**Description**: Preventive health and diagnostics platform using advanced imaging, AI-powered analysis, and comprehensive biomarker testing to enable early detection of diseases and optimize healthspan and lifespan
**Focus**: Preventive health and diagnostics platform using advanced imaging, AI-powered analysis, and comprehensive biomarker testing to enable early detection of diseases and optimize healthspan and lifespan

## Locations

### Biograph New York City Clinic
**Type**: clinic
**City**: New York City
**State/Region**: New York
**Country**: USA
**Organizations**: Biograph

### Biograph San Mateo Headquarters
**Type**: headquarters
**Address**: San Mateo, California
**City**: San Mateo
**State/Region**: California
**Country**: USA
**Organizations**: Biograph

## Products

### Biograph Preventive Diagnostics Platform
**Alternative Names**: Biograph Platform, Biograph Preventive Health Platform
**Type**: platform
**Status**: Commercially available
**Development Stage**: operational
**Role in Project**: primary
**Relationship Description**: Primary product: Comprehensive preventive health assessment platform
**Description**: Comprehensive preventive health assessment platform that collects over 1,000 data points from more than 30 evaluations in a single visit
**Mechanism of Action**: Comprehensive preventive health assessment platform that collects over 1,000 data points from more than 30 evaluations in a single visit. Uses advanced diagnostic technologies including whole-body MRI, CT coronary angiography, AI-powered vascular plaque characterization, multi-cancer early detection testing, multi-modal brain health assessments, metabolic evaluations, and quality of life assessments.
**Target**: Early detection of multiple disease categories
**Pathway**: Preventive medicine through comprehensive biomarker analysis and imaging
**Indications**: [
  {
    "primary": "Early cancer detection",
    "secondary": [
      "Cardiovascular disease risk assessment",
      "Metabolic dysfunction analysis",
      "Neurodegenerative disease evaluation",
      "Quality of life optimization"
    ]
  }
]
**Clinical Trials**:
```yaml
-
  name: AI-Powered Prevention of Heart Disease Study
  phase: Observational Study
  design: First-of-its-kind U.S. study in partnership with Caristo Diagnostics to detect early cardiovascular risk in asymptomatic patients through coronary inflammation detection and plaque quantification using cardiac CT scans
  status: Ongoing
  results:
  status: Enrollment in progress
  summary: Study ongoing, results not yet available
  indication: Early cardiovascular risk detection in asymptomatic patients
  start_date: October 2025
  technology: Caristo Diagnostics CaRi-Heart® and CaRi-Plaque™ AI technology for coronary artery inflammation detection and plaque characterization from cardiac CT scans
  participants: 100 Black Tier members who are clinically appropriate for the study
```
**Technical Details**:
```yaml
notes: Platform is available through membership-based model. Uses FDA-cleared diagnostic equipment and technologies. AI analysis components are integrated with third-party validated technologies.
impact_metrics:
  findings_breakdown:
  cancer: Early-stage cancer detection in asymptomatic individuals
  metabolic: Metabolic dysfunction identification and risk assessment
  cardiovascular: Cardiovascular disease risk identification before symptoms
  neurodegenerative: Early indicators of neurodegenerative conditions
  member_satisfaction: Over 99% of members say they would be disappointed if they could no longer be a Biograph member after receiving their results
  urgent_findings_rate: Over 15% of members discover urgent or life-altering health insights, including early-stage cancer, cardiovascular disease, and neurodegenerative conditions
  data_points_collected: Over 1,000 data points from more than 30 evaluations per visit
membership_tiers:
  -
    name: Core Membership
    price: $7,500
    includes:
    - Whole-body MRI for cancer, multiple sclerosis, and liver disease assessment
    - Comprehensive health evaluations
    - Personalized health plan based on over 1,000 data points from 30+ evaluations
  -
    name: Black Membership
    price: $15,000
    includes:
    - All Core Membership services
    - CT Coronary Angiography
    - AI-powered vascular plaque characterization
    - At-home sleep apnea testing
    - Multi-Cancer Early Detection Testing
    - Multi-Modal Brain Health Assessments
    - Additional advanced screenings
regulatory_status: Available as a preventive health service
```

## Key People

### Dr. Jim Lebret
**Title**: MD
**Participation Type**: leadership
**Role in Project**: Medical Director, New York City Clinic
**Participation Period**: 2025-present
**Biography**: Medical Director of Biograph's New York City clinic

### Dr. Gilberto Hernandez
**Title**: MD
**Participation Type**: leadership
**Role in Project**: Medical Director, San Mateo Clinic
**Participation Period**: 2025-present
**Biography**: Medical Director of Biograph's San Mateo, California clinic

### Dr. Michael Donihi
**Title**: MD
**Participation Type**: leadership
**Role in Project**: Executive Medical Director
**Participation Period**: 2025-present
**Biography**: Executive Medical Director of Biograph

### Dr. Peter Attia
**Title**: MD
**Participation Type**: founder
**Role in Project**: Co-founder
**Participation Period**: 2025-present
**Expertise**: Longevity medicine, preventive health, metabolic health, exercise physiology
**Biography**: Physician, longevity expert, and author of the New York Times bestseller 'Outlive: The Science and Art of Longevity'. MD from Stanford University, trained in general surgery at Johns Hopkins Hospital. Founder of Attia Medical, PC, a medical practice focused on longevity and healthspan optimization.

### John Hering
**Participation Type**: founder
**Role in Project**: Co-founder
**Participation Period**: 2025-present
**Expertise**: Technology entrepreneurship, cybersecurity, healthcare innovation
**Biography**: Entrepreneur and co-founder of Biograph. Previously co-founded Lookout Mobile Security, a cybersecurity company.

## Links

### [The Drive with Peter Attia - Longevity Podcast](https://peterattiamd.com/podcast/)
**Type**: podcast
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Founder's podcast on longevity
**Publisher**: Dr. Peter Attia
**Description**: Dr. Peter Attia's podcast discussing longevity, preventive medicine, and health optimization, providing insight into the scientific foundation of Biograph's approach

### [Outlive: The Science and Art of Longevity by Dr. Peter Attia](https://www.peterattiamd.com/outlive/)
**Type**: book
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Founder's book on longevity
**Publisher**: Dr. Peter Attia
**Description**: Dr. Peter Attia's bestselling book on longevity and preventive medicine, providing context for Biograph's approach

### [Siemens Healthineers Announces FDA Clearance of Biograph Vision.X PET/CT Scanner](https://www.siemens-healthineers.com/en-us/press-room/press-releases/biograph-vision-x-fda-clearance)
**Type**: press_release
**Relevance**: secondary
**Category**: reference
**Relationship Description**: Related diagnostic imaging technology
**Publisher**: Siemens Healthineers
**Publication Date**: 2023-11-22
**Description**: Information about Biograph Vision.X PET/CT scanner technology used in advanced diagnostic imaging

### [Startup co-founded by longevity guru Peter Attia emerges from stealth](https://techcrunch.com/2025/02/28/startup-co-founded-by-longevity-guru-peter-attia-emerges-from-stealth/)
**Type**: news_article
**Relevance**: primary
**Category**: source
**Relationship Description**: TechCrunch coverage of launch
**Publisher**: TechCrunch
**Publication Date**: 2025-02-28
**Description**: TechCrunch article about Biograph's launch and Dr. Peter Attia's involvement

### [How Biograph Works – Longevity Health Plan & Comprehensive Evaluation](https://www.biograph.com/how-biograph-works)
**Type**: website
**Relevance**: secondary
**Category**: source
**Relationship Description**: Platform explanation and methodology
**Publisher**: Biograph
**Description**: Detailed explanation of how Biograph's platform works and what members can expect

### [Frequently Asked Questions - Biograph Preventive Health & Longevity](https://www.biograph.com/faq)
**Type**: website
**Relevance**: secondary
**Category**: source
**Relationship Description**: FAQ page with service information
**Publisher**: Biograph
**Description**: FAQ page with information about Biograph's services and membership

### [Biograph, a new whole-body MRI startup, launches with $7,500 membership fee](https://radiologybusiness.com/topics/healthcare-management/healthcare-economics/biograph-new-whole-body-mri-startup-launches-7500-membership-fee)
**Type**: news_article
**Relevance**: primary
**Category**: source
**Relationship Description**: News coverage of launch and pricing
**Publisher**: Radiology Business
**Publication Date**: 2025-02-28
**Description**: News article about Biograph's launch and membership pricing

### [Pioneering the Future of Heart Health: Biograph and Caristo Diagnostics Announce First-of-its-Kind U.S. Study to Advance AI-Powered Prevention](https://www.prnewswire.com/news-releases/pioneering-the-future-of-heart-health-biograph-and-caristo-diagnostics-announce-first-of-its-kind-us-study-to-advance-ai-powered-prevention-302570592.html)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Relationship Description**: Caristo Diagnostics partnership announcement
**Publisher**: PR Newswire
**Publication Date**: 2025-09-30
**Description**: Press release announcing Biograph's partnership with Caristo Diagnostics for AI-powered cardiovascular risk detection study

### [Biograph Opens its New York City Clinic, Transforming the Personalized Healthcare Experience](https://www.businesswire.com/news/home/20250520281301/en/Biograph-Opens-its-New-York-City-Clinic-Transforming-the-Personalized-Healthcare-Experience)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Relationship Description**: New York City clinic opening announcement
**Publisher**: Business Wire
**Publication Date**: 2025-05-20
**Description**: Press release announcing the opening of Biograph's New York City flagship clinic

### [Biograph, the World's Most Advanced Preventive Health and Diagnostics Clinic, Launches to Redefine Healthy Aging and Set New Industry Standards](https://www.businesswire.com/news/home/20250227400955/en/Biograph-the-Worlds-Most-Advanced-Preventive-Health-and-Diagnostics-Clinic-Launches-to-Redefine-Healthy-Aging-and-Set-New-Industry-Standards)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Relationship Description**: Public launch announcement
**Publisher**: Business Wire
**Publication Date**: 2025-02-27
**Description**: Official press release announcing Biograph's public launch in February 2025

## Events

### Public Launch
**Date**: 2025-02-01
**Type**: launch
**Description**: Biograph emerged from stealth and officially launched as 'the world's most advanced preventive health and diagnostics clinic', aiming to redefine healthy aging and set new industry standards. First clinic opened in San Mateo, California.
**Details**:
```yaml
announcement: "Biograph, the World's Most Advanced Preventive Health and Diagnostics Clinic, Launches to Redefine Healthy Aging and Set New Industry Standards"
```

### Clinic Opening
**Date**: 2025-05-01
**Type**: expansion
**Description**: Biograph opened its flagship clinic in New York City, offering a personalized and serene healthcare experience. The New York clinic represents the company's expansion beyond the San Francisco Bay Area.
**Details**:
```yaml
announcement: Biograph Opens its New York City Clinic, Transforming the Personalized Healthcare Experience
```

### Partnership Announcement
**Date**: 2025-09-01
**Type**: partnership
**Description**: Biograph announced partnership with Caristo Diagnostics to conduct the first-of-its-kind U.S. study on AI-powered prevention of heart disease. The study will use Caristo's CaRi-Heart® and CaRi-Plaque™ AI technology to detect coronary artery inflammation from cardiac CT scans in asymptomatic patients.
**Details**:
```yaml
announcement: "Pioneering the Future of Heart Health: Biograph and Caristo Diagnostics Announce First-of-its-Kind U.S. Study to Advance AI-Powered Prevention"
```

### Clinical Study Initiation
**Date**: 2025-10-01
**Type**: study_start
**Description**: Biograph and Caristo Diagnostics initiated enrollment for their joint study on early cardiovascular risk detection. The study is open to 100 Black Tier members who are clinically appropriate for the research.
**Details**:
```yaml

```

## Partnerships

### research
**Date**: 2025-09-01
**Focus**: Early cardiovascular risk detection in asymptomatic patients
**Description**: Partnership to conduct the first-of-its-kind U.S. study on AI-powered prevention of heart disease. The collaboration uses Caristo's CaRi-Heart® and CaRi-Plaque™ AI technology to detect coronary artery inflammation and characterize plaque from cardiac CT scans in asymptomatic patients. The study aims to determine if detecting coronary artery inflammation and plaque characterization can identify early stages of cardiovascular disease in asymptomatic patients.
**Partner Organizations**:
- Caristo Diagnostics (partner)
- Biograph (primary)
**Details**:
```yaml
url: "https://www.caristo.com/"
technology: CaRi-Heart® and CaRi-Plaque™ AI technology
```
